6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
| Status: | Archived |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | January 2009 |
Randomised Phase II Study of Neoadjuvant BIBW 2992 Versus Herceptin Versus Lapatinib in Her2 Positive Breast Cancer Patients
An open-label, randomized three-arm Phase II trial to explore the efficacy of BIBW 2992 as a
single agent versus lapatinib versus trastuzumab in patients with HER2-positive
treatment-naïve Stage IIIa locally advanced breast cancer. Additional information will be
obtained on the safety profile and pharmacokinetics of BIBW 2992.
We found this trial at
1
site
Click here to add this to my saved trials
